Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 3/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.48 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.48 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.48 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 15/20 | 0.47 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.38 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.38 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.38 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | RAF1 | P04049 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2930799 | 0.93 | MAPK14 (0.44) | CSNK1DMAP4K4MAPK9CSNK1A1CDC42BPA | |
| SCHEMBL2930582 | 0.90 | SIGMAR1 (0.41) | CSNK1DMAP4K4MAPK9CSNK1A1CDC42BPA | |
| SCHEMBL1383829 | 0.89 | MAP4K4 (0.46) | CSNK1DMAP4K4MAPK9CSNK1A1CDC42BPA | |
| SCHEMBL29652680 | 0.86 | MAPK14 (0.46) | CSNK1DCSNK1A1MAPK14MAPK13CSNK1E | |
| SCHEMBL2926671 | 0.86 | ALOX5 (0.42) | CSNK1DCSNK1A1MAPK14MAPK13CSNK1E | |
| SCHEMBL2927923 | 0.85 | MAPK14 (0.46) | MAPK14MAPK13MAPK12MAPK11SIGMAR1 | |
| SCHEMBL2929824 | 0.84 | MAPK14 (0.46) | CSNK1DCSNK1A1MAPK14MAPK13CSNK1E | |
| SCHEMBL1386735 | 0.83 | CYP17A1 (0.44) | CSNK1DCSNK1A1MAPK14MAPK13CSNK1E | |
| SCHEMBL1385796 | 0.83 | MAPK14 (0.44) | CSNK1DMAP4K4MAPK9CSNK1A1CDC42BPA | |
| SCHEMBL1384557 | 0.82 | MAPK14 (0.46) | MAPK14MAPK13MAPK12MAPK11EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1611131-B1 | PYRAZOLOPYRIDINE DERIVATES | PALAU PHARMA SA (ES) | 2010-09-15 | — | — | EP | claimed |
| US-20090005377-A1 | Pyrazolopyridine Derivates | PALAU PHARMA, S.A. (ES) | 2009-01-01 | — | — | US | claimed |
| US-7468376-B2 | Pyrazolopyridine derivates | PALAU PHARMA, S.A. (ES) | 2008-12-23 | — | — | US | claimed |
| US-20060167040-A1 | Pyrazolopyridine derivates | J. URIACH Y COMPANIA S.A. (ES) | 2006-07-27 | — | — | US | claimed |
| US-8536194-B2 | Pyrazolopyridine derivates | PALAU PHARMA, S.A. (ES) | 2013-09-17 | — | — | US | disclosed |
| EP-1611131-B1 | PYRAZOLOPYRIDINE DERIVATES | PALAU PHARMA SA (ES) | 2010-09-15 | — | — | EP | disclosed |
| US-20090286983-A1 | Pyrazolopyridine Derivates | PALAU PHARMA, S.A. (ES) | 2009-11-19 | — | — | US | disclosed |
| US-20090005377-A1 | Pyrazolopyridine Derivates | PALAU PHARMA, S.A. (ES) | 2009-01-01 | — | — | US | disclosed |
| US-7468376-B2 | Pyrazolopyridine derivates | PALAU PHARMA, S.A. (ES) | 2008-12-23 | — | — | US | disclosed |
| US-20060167040-A1 | Pyrazolopyridine derivates | J. URIACH Y COMPANIA S.A. (ES) | 2006-07-27 | — | — | US | disclosed |
| EP-1611131-A1 | PYRAZOLOPYRIDINE DERIVATES | J. Uriach y Compagnia S.A. (ES) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004076450-A1 | PYRAZOLOPYRIDINE DERIVATES | J. Uriach Y Compañia S.A. (ES) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167040-A1 | Pyrazolopyridine derivates | MAPK1, MAP4K2, MAP4K3 | CSNK1D 75/4885MAP4K4 24/4885MAPK9 33/4885 |
| US-20090286983-A1 | Pyrazolopyridine Derivates | MAPK1, MAPK4, MAP4K2 | CSNK1D 60/4885MAP4K4 32/4885MAPK9 29/4885 |
| US-20090005377-A1 | Pyrazolopyridine Derivates | MAPK1, MAPK4, MAP4K2 | CSNK1D 60/4885MAP4K4 32/4885MAPK9 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.